Table 3 Inhibitory potential of a variety of HIV-1 inhibitors towards WT and mutant virus strains containing the N674D mutation or a combination of glycan deletions in gp41
|  | Nr | HHA (nM) | UDA (nM) | AH (nM) | 2G12 (nM) | PRM-S ( μM) | T-20 (nM) | AMD3100 (nM) |
|---|---|---|---|---|---|---|---|---|
WT |  | 0.9 ± 0.2 | 25 ± 3 | 5.2 ± 1.0 | 1.1 ± 0.2 | 4.8 ± 0.4 | 340 ± 141 | 3.5 ± 0.6 |
N674D |  | 1.9 ± 0.6 | 34 ± 10 | 2.1 ± 0.5 | 0.8 ± 0.2 | 4.7 ± 0.4 | 63 ± 20 | 3.3 ± 0.3 |
N611Q/N637Q | #2 | 2.7 ± 0.4 | 63 ± 7 | 3.0 ± 0.7 | 0.5 ± 0.1 | 4.8 ± 0.4 | 49 ± 4 | 3.5 ± 0.3 |
N625Q/N637Q | #4 | 1.4 ± 0.2 | 51 ± 6 | 3.8 ± 0.1 | 0.8 ± 0.2 | 5.3 ± 0.1 | 21 ± 2 | 3.3 ± 0.4 |
N625Q/N674Q | #5 | 1.3 ± 0.3 | 30 ± 2 | 3.2 ± 0.3 | 0.9 ± 0.1 | 5.3 ± 0.1 | 57 ± 4 | 3.5 ± 0.1 |
N637Q/N674Q | #6 | 1.6 ± 0.5 | 28 ± 10 | 4.3 ± 0.9 | 0.9 ± 0.0 | 5.3 ± 0.1 | 48 ± 24 | 3.6 ± 0.3 |
N625Q/N637Q/N674Q | #B | 2.1 ± 0.1 | 35 ± 6 | 3.2 ± 0.7 | 0.5 ± 0.1 | 5.0 ± 0.1 | 20 ± 2 | 3.5 ± 0.3 |
N611Q/N637Q/N674Q | #C | 2.8 ± 0.6 | 52 ± 7 | 3.6 ± 0.4 | 0.6 ± 0.0 | 5.3 ± 0.2 | 56 ± 10 | 3.3 ± 0.2 |